Recent Updates
Recently added Catalysts

LY3372993

Phase 1

Healthy | Small molecule | Other |Eli Lilly and Company|Last Updated: Apr 20, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment24
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07346495A Study of Remternetug (LY3372993) in Healthy Chinese ParticipantsPHASE1 ACTIVE NOT_RECRUITING 24 — — Jan 31, 2026Jan 1, 2027Apr 20, 20262 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline through study completion up to 25 weeks
Secondary Endpoints
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Remternetug
Day 1 through Day 5
PK: Area Under the Concentration Versus Time Curve (AUC) of Remternetug
Day 1 through Day 5
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
RemternetugEXPERIMENTALRemternetug will be administered subcutaneously (SC)
PlaceboPLACEBO_COMPARATORPlacebo will be administered Subcutaneously (SC)
Interventions
NameTypeDescription
LY3372993DRUGAdministered SC
PlaceboDRUGAdministered SC
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, electrocardiogram (ECG), and Magnetic resonance imaging (MRI). * Participants must be native Chinese. To qualify as Chinese for this stud...

Countries:China
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT07346495Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWMay 24, 2026NCT07346495studyFirstPostDate: changed